Merck Shores Up Vioxx Legal Reserve; SEC Initiates Formal Inquiry
This article was originally published in The Tan Sheet
Executive Summary
Merck's $675 mil. legal reserve related to Vioxx appears to be only a starting point in ongoing litigation
You may also be interested in...
Pfizer COX-2 Marketing, Safety Practices Questioned By DoJ
Pfizer is working to supply the Justice Department and several state attorneys general with materials related to the company's handling of marketing and safety issues associated with Celebrex and Bextra
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands